Siren Song Of Lupus Has Left A Legacy Of Failed Trials

The five-decade drought in FDA approvals of lupus therapies – broken by Human Genome Sciences Inc.'s recent launch of Benlysta – featured a steady stream of drug developers that were not dissuaded by the legacy of trial failures and shifting regulatory standards that marked the field, only to join the ranks of clinical failures in lupus.